Sano Chemicals has begun its phase 1, first-in-human clinical trial of Occidiofungin, a new treatment to cure recurrent vaginal yeast infections or vulvovaginal candidiasis (RVVC).
Colleen Acosta is CEO of Freya Biosciences which is a trans-Atlantic clinical-stage biotech company pioneering microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of women’s reproductive system conditions and we were...